Prophylaxis in children with hemophilia: Evidence-based achievements, old and new challenges

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 1, 2012, Pages 79-94

  Coppola, Antonio ^a   Tagliaferri, Annarita ^b   Di Capua, Mirko ^a   Franchini, Massimo ^c  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c CARLO POMA HOSPITAL   (Italy)

Author keywords

arthropathy; bleeding; children; hemophilia; hemophilic; prophylaxis; quality of life

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

CHILD; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE;

EID: 84857019132     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1300954     Document Type: Conference Paper

References (119)

1. Mannucci PM, Tuddenham EG. The hemophiliasfrom royal genes to gene therapy. N Engl J Med: 2001; 344 23 1773 1779 (Pubitemid 32497033)
2. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand: 1962; 171 237 242
3. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl: 1965;;(Suppl 77 77, 3-132
4. van den Berg HM, De Groot PHG, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost: 2007; 5 Suppl 1 151 156 (Pubitemid 46958828)
5. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J.; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost: 2001; 85 3 560 (Pubitemid 32233035)
6. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia: 2006; 12 Suppl 3 117 121
7. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia: 2008; 14 Suppl 3 10 18 (Pubitemid 351722377)
8. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med: 1992; 232 1 25 32
9. Berntorp E, Boulyjenkov V, Brettler D., et al. Modern treatment of haemophilia. Bull World Health Organ: 1995; 73 5 691 701 (Pubitemid 26020631)
10. Srivastava A, Giangrande P, Poon MC., et al. Guidelines for the Management of Hemophilia. World Federation of Hemophilia, 2005. Available at: http://www.wfh.org/2/docs/Publications/Diagnosis-and-Treatment/ Guidelines-Mng-Hemophilia.pdf. Last accessed 16 September 2011
11. Manco-Johnson MJ, Abshire TC, Shapiro AD., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med: 2007; 357 6 535 544 (Pubitemid 47236278)
12. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM.; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT study). J Thromb Haemost: 2011; 9 4 700 710
13. Evatt BL, Black C, Batorova A, Street A, Srivastava A. Comprehensive care for haemophilia around the world. Haemophilia: 2004; 10 Suppl 4 9 13 (Pubitemid 40045413)
14. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy global progress towards optimal care. Haemophilia: 2006; 12 1 75 81
15. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost: 2009; 101 4 674 681
16. Aledort LM, Haschmeyer RH, Pettersson H.; The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med: 1994; 236 4 391 399 (Pubitemid 24323199)
17. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol: 1993; 30 3 Suppl 2 3 6 (Pubitemid 23212308)
18. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res: 1980; 149 149 153 159 (Pubitemid 10082434)
19. Fischer K, van der Bom JG, Mauser-Bunschoten EP., et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood: 2002; 99 7 2337 2341 (Pubitemid 34525418)
20. Gringeri A, von Mackensen S, Auerswald G., et al. Haemo-QoL Study. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia: 2004; 10 Suppl 1 26 33 (Pubitemid 40045397)
21. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?The German experience. Haemophilia: 1998; 4 4 413 417 (Pubitemid 28351856)
22. van den Berg HM, Fischer K, Mauser-Bunschoten EP., et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol: 2001; 112 3 561 565 (Pubitemid 32222823)
23. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia: 2003; 9 3 272 278 (Pubitemid 36622028)
24. Yee TT, Beeton K, Griffioen A., et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia: 2002; 8 2 76 82 (Pubitemid 35238059)
25. Berntorp E, Astermark J, Björkman S., et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia: 2003; 9 Suppl 1 1 4 (Pubitemid 36622042)
26. Donadel-Claeyssens S.; European Paediatric Network for Haemophilia Management. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia: 2006; 12 2 124 127
27. Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia: 2004; 10 2 147 157 (Pubitemid 38312641)
28. Ljung R. Prophylactic therapy in haemophilia. Blood Rev: 2009; 23 6 267 274
29. National Hemophilia Foundation. Medical and Scientific Advisory Council. MASAC Recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Document 170. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid= 582. Accessed on September 16, 2011
30. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol: 1999; 105 4 1109 1113 (Pubitemid 29309124)
31. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia: 2001; 7 1 99 102 (Pubitemid 32162205)
32. Richards M, Williams M, Chalmers E., et al. Paediatric Working Party of the United Kingdom Haemophilia Doctors Organisation. A United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol: 2010; 149 4 498 507
33. Feldman BM, Pai M, Rivard GE., et al. Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost: 2006; 4 6 1228 1236
34. Hang MX, Blanchette VS, Pullenayegum E, McLimont M, Feldman BM.; Canadian Hemophilia Primary Prophylaxis Study Group. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost: 2011; 9 5 1067 1069
35. Carcao M, Chambost H, Ljung R. Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies. Haemophilia: 2010; 16 Suppl 2 4 9
36. Meunier S, Trossart N, Berger C., et al. French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemopiliac arthropathy. Arch Pediatr: 2009; 16 1571 1578
37. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia: 2007; 13 Suppl 2 16 22 (Pubitemid 47034490)
38. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis: 1992; 22 5 251 258 (Pubitemid 23000361)
39. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol: 1994; 47 2 113 117 (Pubitemid 24302280)
40. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol: 1996; 92 4 973 978 (Pubitemid 26109507)
41. Cohen A, White E, Bernstein C., et al. Effects of secondary prophylaxis in hemophilia children with frequent hemarthrosis. Transfusion: 1997; 37 534 535
42. Tagliaferri A, Franchini M, Coppola A., et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia: 2008; 14 5 945 951
43. Franchini M, Coppola A, Molinari AC., et al. Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Haemophilia: 2009; 15 2 578 586
44. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev: 2005; 2 2 CD003429
45. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev: 2011; 9 CD003429
46. Kilcoyne RF, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia: 2003; 9 Suppl 1 57 63, discussion 63-64
47. Doria AS, Lundin B, Kilcoyne RF., et al. Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: expert MRI Working Group of the International Prophylaxis Study Group. Haemophilia: 2005; 11 3 245 253 (Pubitemid 40723800)
48. von Mackensen S, Bullinger M.; Haemo-QoL Group. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia: 2004; 10 Suppl 1 17 25 (Pubitemid 40045396)
49. Colvin BT, Astermark J, Fischer K., et al. Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia: 2008; 14 2 361 374 (Pubitemid 351338698)
50. Vidler V. Teaching parents advanced clinical skills. Haemophilia: 1999; 5 5 349 353 (Pubitemid 29495712)
51. De Moerloose P, Urbancik W, Van Den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia: 2008; 14 5 931 938
52. Collins PW, Blanchette VS, Fischer K., et al. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost: 2009; 7 3 413 420
53. Fischer K, Collins P, Björkman S., et al. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. Haemophilia: 2011; 17 3 433 438
54. Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia: 2000; 6 6 649 657
55. Hill FG, Ljung R.; European Paediatric Network for Haemophilia Management. Third and fourth Workshops of the European Paediatric Network for Haemophilia Management. Haemophilia: 2003; 9 2 223 228 (Pubitemid 36511660)
56. Hilliard P, Funk S, Zourikian N., et al. Hemophilia joint health score reliability study. Haemophilia: 2006; 12 5 518 525 (Pubitemid 44227596)
57. Lundin B, Babyn P, Doria AS., et al. International Prophylaxis Study Group. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia: 2005; 11 2 109 115 (Pubitemid 40468058)
58. Doria AS. State-of-the-art imaging techniques for the evaluation of haemophilic arthropathy: present and future. Haemophilia: 2010; 16 Suppl 5 107 114
59. Keshava S, Gibikote S, Mohanta A, Doria AS. Refinement of a sonographic protocol for assessment of haemophilic arthropathy. Haemophilia: 2009; 15 5 1168 1171
60. Melchiorre D, Linari S, Innocenti M., et al. Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score. Haemophilia: 2011; 17 1 112 117
61. Blanchette VS, Shapiro AD, Liesner RJ., et al. rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost: 2008; 6 8 1319 1326 (Pubitemid 352016311)
62. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol: 2009; 65 10 989 998
63. Collins PW, Björkman S, Fischer K., et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost: 2010; 8 2 269 275
64. Carlsson M, Berntorp E, Bjorkman S., et al. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of hemophilia A. Haemophilia: 1997; 3 96 101 (Pubitemid 27187173)
65. Morfini M, Lee M, Messori A.; Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost: 1991; 66 3 384 386
66. Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia: 2004; 10 6 689 697 (Pubitemid 40028584)
67. Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia: 2003; 9 Suppl 1 94 99, discussion 100
68. Shapiro AD, Korth-Bradley J, Poon M-C. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia: 2005; 11 6 571 582 (Pubitemid 41631591)
69. Fischer K, van der Bom JG, van den Berg HM. Health-related quality of life as outcome parameter in haemophilia treatment. Haemophilia: 2003; 9 Suppl 1 75 81, discussion 82
70. Coppola A, Cerbone AM, Mancuso G, Mansueto MF, Mazzini C, Zanon E. Confronting the psychological burden of haemophilia. Haemophilia: 2011; 17 1 21 27
71. van Genderen FR, van Meeteren NL, van der Bom JG., et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia: 2004; 10 5 565 571
72. Gringeri A, Von Mackensen S. Quality of life in haemophilia. Haemophilia: 2008; 14 Suppl 3 19 25 (Pubitemid 351722378)
73. Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, McCusker PJ. How well does the Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia? Pediatr Blood Cancer: 2006; 47 3 305 311 (Pubitemid 44148048)
74. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia: 2003; 9 4 418 435 (Pubitemid 36874391)
75. Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia: 2006; 12 Suppl 6 54 61 (Pubitemid 44741503)
76. Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia: 2010; 16 Suppl 2 16 23
77. Gringeri A, Mantovani LG, Scalone L, Mannucci PM.; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood: 2003; 102 7 2358 2363 (Pubitemid 37193570)
78. Scalone L, Mantovani LG, Mannucci PM, Gringeri A.; COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia: 2006; 12 2 154 162
79. Coppola A, Santoro C, Tagliaferri A, Franchini M, DI Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia: 2010; 16 Suppl 1 13 19
80. Matzinger P. The danger model: a renewed sense of self. Science: 2002; 296 5566 301 305 (Pubitemid 34303674)
81. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood: 2007; 109 11 4648 4654 (Pubitemid 46827754)
82. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost: 2007; 5 7 1383 1390 (Pubitemid 46965364)
83. Gouw SC, van den Berg HM, van der Bom JG. on behalf of the PedNet Study Group and the RODIN Study Group. Treatment-related risk factors of inhibitor development in patients with severe hemophilia A: the RODIN Study. J Thromb Haemost: 2011; 9 Suppl 2 21
84. Knobe KE, Sjörin E, Tengborn LI, Petrini P, Ljung RC. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr: 2002; 91 8 910 914 (Pubitemid 34876224)
85. Morado M, Villar A, Jimnez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia: 2005; 11 2 79 83 (Pubitemid 40468053)
86. Santagostino E, Mancuso ME, Rocino A., et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol: 2005; 130 3 422 427 (Pubitemid 43899592)
87. Maclean PS, Richards M, Williams M., et al. Paediatric Working Party of UKHCDO. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia: 2011; 17 2 282 287
88. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia: 2010; 16 2 256 262
89. Plug I, van der Bom JG, Peters M., et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood: 2004; 104 12 3494 3500 (Pubitemid 39564418)
90. Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD.; Association of Hemophilia Clinic Directors of Canada (AHCDC); Canadian Association of Nurses in Hemophilia Care (CANHC). The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia: 2008; 14 5 923 930
91. Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapya survey of treatment centres in the United States. Haemophilia: 2003; 9 5 549 554 (Pubitemid 37236089)
92. Taki M, Shirahata A. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan. Haemophilia: 2009; 15 1 78 82
93. Fischer K, van der Bom JG, Molho P., et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia: 2002; 8 6 745 752 (Pubitemid 35446626)
94. Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia: 2008; 14 4 743 752 (Pubitemid 352016030)
95. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia: 2005; 11 5 438 443 (Pubitemid 41283110)
96. Fischer K, Van Der Bom JG, Prejs R., et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia: 2001; 7 6 544 550 (Pubitemid 34026747)
97. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol: 2005; 130 1 107 112 (Pubitemid 40979141)
98. Santagostino E, Mancuso ME, Tripodi A., et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost: 2010; 8 4 737 743
99. Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia: 2008; 14 Suppl 3 196 201 (Pubitemid 351722402)
100. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia: 2004; 10 2 134 146 (Pubitemid 38312640)
101. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol: 2007; 138 5 580 586 (Pubitemid 47206720)
102. Mancuso ME, Mannucci PM, Sartori A, Agliardi A, Santagostino E. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters. Br J Haematol: 2008; 141 5 689 695 (Pubitemid 351667622)
103. Ljung R, Chambost H, Stain AM, DiMichele D. Haemophilia in the first years of life. Haemophilia: 2008; 14 Suppl 3 188 195 (Pubitemid 351722401)
104. Mancuso ME, Berardinelli L, Beretta C, Raiteri M, Pozzoli E, Santagostino E. Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. Haematologica: 2009; 94 5 687 692
105. Bui S, Babre F, Hauchecorne S., et al. Intravenous peripherally-inserted central catheters for antibiotic therapy in children with cystic fibrosis. J Cyst Fibros: 2009; 8 5 326 331
106. Hatakeyama N, Hori T, Yamamoto M., et al. An evaluation of peripherally inserted central venous catheters for children with cancer requiring long-term venous access. Int J Hematol: 2011; 94 4 372 377
107. Fischer K, Astermark J, van der Bom JG., et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia: 2002; 8 6 753 760 (Pubitemid 35446627)
108. van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia: 2003; 9 Suppl 1 27 31, discussion 31 (Pubitemid 36622046)
109. Wu R, Luke KH, Poon M-C., et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia: 2011; 17 1 70 74
110. Celkan T, zdemir N. Reduced early prophylaxis of children with haemophilia in a developing country, Turkey. Haemophilia: 2011; 17 5 e840 e841
111. National Hemophilia Foundation. Medical and Scientific Advisory Council. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Recommendation 179. (2007). Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid= 57&contentid=1007. Accessed on September 16, 2011
112. Tagariello G, Iorio A, Santagostino E., et al. Italian Association Hemophilia Centre (AICE). Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood: 2009; 114 4 779 784
113. den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia: 2009; 15 1 83 90
114. Konkle BA, Ebbesen LS, Erhardtsen E., et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost: 2007; 5 9 1904 1913 (Pubitemid 47288949)
115. Leissinger C, Gringeri A, Antmen B., et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med: 2011; 365 18 1684 1692
116. Jimnez-Yuste V, Alvarez MT, Martn-Salces M., et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia: 2009; 15 1 203 209
117. Santagostino E, Auerswald G, Jimenez-Yuste V., et al. European Initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study. Haemophilia: 2010; 16 2 407
118. Nicholson A, Berger K, Bohn R., et al. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. Haemophilia: 2008; 14 1 127 132
119. Pipe SW. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program: 2010; 2010 203 209